Opioid peptides: Potential for drug development

Drug Discovery Today: Technologies

Volumn 9, Issue 1, 2012, Pages

  Aldrich, Jane V ^a   McLaughlin, Jay P ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINOCICEPTIVE AGENT; BIPHALIN; CJ 15208; CJC 1008; CR 665; CR 845; DERMORPHIN DERIVATIVE; DYNORPHIN A DERIVATIVE; DYNORPHIN A [1-8][1 (N METHYLTYROSINE) 7 (N METHYLARGININE) 8 DEXTRO LEUCINE N ETHYLAMIDE]; DYNORPHIN[1-13]; DYNORPHIN[1-8]; ENDOMORPHIN 2; ENKEPHALIN DERIVATIVE; FE 200041; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; METENKEPHALIN; MMP 2200; MORPHINE; MZ 2; OPIATE PEPTIDE; OPIATE RECEPTOR; PENTAZOCINE; PROENKEPHALIN; SK 9709; TETRAPEPTIDE; TY 005; UNCLASSIFIED DRUG; ZYKLOPHIN;

ANALGESIA; CANCER PAIN; DRUG BIOAVAILABILITY; DRUG STABILITY; GLYCOSYLATION; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; NONHUMAN; PAIN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; REVIEW; VISCERAL PAIN; WITHDRAWAL SYNDROME;

EID: 84865692038     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2011.07.007     Document Type: Review

References (40)

1. Aldrich, J.V. and Vigil-Cruz, S.C. (2003) Narcotic analgesics. In Burger's Medicinal Chemistry & Drug Discovery (Vol. 6) (Abraham, D.J., ed.), pp. 329-481, John Wiley & Sons, Inc.
2. Aldrich, J.V. (2009) Opioid peptides. In Bioactive Peptides (Howl, J. and Jones, S., eds.), pp. 103-136, CRC Press
3. Aldrich, J.V. and McLaughlin, J.P. (2009) Peptide kappa opioid receptor ligands: Potential for drug development. AAPS J. 11, 312-322
4. Schiller, P.W. (2010) Bi- or multifunctional opioid peptide drugs. Life Sci. 598-603
5. Janecka, A. et al. (2010) Development of opioid peptide analogs for pain relief. Curr. Pharm. Des. 16, 1126-1135
6. Vanderah, T.W. (2010) Delta and kappa opioid receptors as suitable drug targets for pain. Clin. J. Pain 26 (Suppl. 10), S10-S15
7. Chaki, K. et al. (1988) Comparison of the antinociceptive effects of new [DArg]-dermorphin tetrapeptide analogs and morphine in mice. Pharmacol. Biochem. Behav. 31, 439-444 (Pubitemid 19275166)
8. Ogawa, T. et al. (2002) Synthesis and structure-activity relationships of an orally available and long-acting analgesic peptide, Na-amidino-Tyr-D-Arg- Phe-MebAla-OH (ADAMB). J. Med. Chem. 45, 5081-5089 (Pubitemid 35278704)
9. Mizoguchi, H. et al. (2011) Dermorphin tetrapeptide analogs as potent and long-lasting analgesics with pharmacological profiles distinct from morphine. Peptides 32, 421-427
10. Liu, H.M. et al. (2006) Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1. J. Pharmacol. Exp. Ther. 319, 308-316
11. Bryant, S.D. et al. (2003) Dmt and opioid peptides: A potent alliance. Biopolym. (Peptide Sci.) 71, 86-102 (Pubitemid 36702314)
12. Jutkiewicz, E.M. (2006) The antidepressant-like effects of delta-opioid receptor agonists. Mol. Interv. 6, 162-169 (Pubitemid 43998814)
13. Aguila, B. et al. (2007) In vitro and in vivo pharmacological profile of UFP-512, a novel selective d-opioid receptor agonist; correlations between desensitization and tolerance. Br. J. Pharmacol. 152, 1312-1324 (Pubitemid 350242435)
14. Vergura, R. et al. (2008) Anxiolytic- and antidepressant-like activities of HDmt- Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides 29, 93-103 (Pubitemid 50008818)
15. Mabrouk, O.S. et al. (2009) The novel delta opioid receptor agonist UFP-dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway. Neuroscience 164, 360-369
16. Jinsmaa, Y. et al. (2008) Inhibition of the development of morphine tolerance by a potent dual m-/d-opioid antagonist, H-Dmt-Tic-Lys-NHCH2- Ph. Pharmacol. Biochem. Behav. 90, 651-657
17. Marczak, E.D. et al. (2009) Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent m-/d-opioid receptor antagonist, regulates obese-related factors in mice. Eur. J. Pharmacol. 616, 115-121
18. Largent-Milnes, T.M. et al. (2010) Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Br. J. Pharmacol. 161, 986-1001
19. Hiramatsu, M. et al. (2001) Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-ArgC(CH2NH) Arg-NH2, in mice. Br. J. Pharmacol. 132, 1948-1956 (Pubitemid 32397988)
20. Vats, I.D. et al. (2008) YFa, a chimeric opioid peptide, induces kappaspecific antinociception with no tolerance development during 6 days of chronic treatment. J. Neurosci. Res. 86, 1599-1607 (Pubitemid 351642453)
21. Vats, I.D. et al. (2010) Effect of chronic intra-peritoneally administered chimeric peptide of met-enkephalin and FMRFa-[D-Ala2]YFa-on antinociception and opioid receptor regulation. Eur J. Pain 14 e295.e1- e295.e9
22. Vats, I.D. et al. (2010) Rationally designed chimeric peptide of Metenkephalin and FMRFa-[D-Ala2,p-Cl-Phe4]YFa induce multiple opioid receptors mediated antinociception and up-regulate their expression. Eur. J. Pharmacol. 638, 54-60
23. Brugos, B. et al. (2004) Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: Effect of different routes of administration. AAPS J. 6, e36
24. Aldrich, J.V. et al. (2009) Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc. Natl. Acad. Sci. U.S.A. 106, 18396-18401
25. Witt, K.A. and Davis, T.P. (2006) CNS drug delivery: Opioid peptides and the blood-brain barrier. AAPS J. 8, E76-E88 (Pubitemid 43349387)
26. Polt, R. et al. (2005) Glycosylated neuropeptides: A new vista for neuropsychopharmacology? Med. Res. Rev. 25, 557-585 (Pubitemid 41233371)
27. Lowery, J.J. et al. (2011) In vivo characterization of MMP-2200, a mixed d/m opioid agonist, in mice. J. Pharmacol. Exp. Ther. 336, 767-778
28. Do Carmo, G.P. et al. (2008) Behavioral pharmacology of the d/m opioid glycopeptide MMP2200 in rhesus monkeys. J. Pharmacol. Exp. Ther. 326, 939-948
29. Witt, K.A. et al. (2001) Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to met-enkephalin analog [D-Pen2,D-Pen5]-enkephalin (DPDPE). J. Pharmacol. Exp. Ther. 298, 848-856 (Pubitemid 32673439)
30. Huber, J.D. et al. (2003) Conjugation of low molecular weight poly(ethylene glycol) to biphalin enhances antinociceptive profile. J. Pharm. Sci. 92, 1377-1385 (Pubitemid 36792751)
31. Bedini, A. et al. (2010) Peripheral antinociceptive effects of the cyclic endomorphin-1 analog c[YpwFG] in a mouse visceral pain model. Peptides 2135-2140
32. Ross, N.C. et al. Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting kappa opioid receptor antagonism. Br. J. Pharmacol. (in press) doi:10.1111/j.1476-2011. 01544.x
33. Vanderah, T.W. et al. (2004) FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious k opioid agonist with unprecedented selectivity. J. Pharmacol. Exp. Ther. 310, 326-333 (Pubitemid 38812727)
34. Vanderah, T.W. et al. (2008) Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral k-opioid receptors. Eur. J. Pharmacol. 583, 62-72
35. Wallace, M.S. et al. (2006) A Phase II, multicenter, randomized, doubleblind, placebo-controlled crossover study of CJC-1008 - a long-acting, parenteral opioid analgesic - in the treatment of postherpetic neuralgia. J. Opioid Manag. 2, 167-173
36. Arendt-Nielsen, L. et al. (2009) Analgesic efficacy of peripheral k-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multitissue experimental human pain model: Selective effect on visceral pain. Anesthesiology 111, 616-624
37. Smith, J.P. et al. (2010) Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J. Clin. Trials 2010, 37-48
38. Fink, D.J. et al. (2011) Gene therapy for pain: Results of a Phase I clinical trial. Ann. Neurol. 70, 207-212
39. Marx, M. (2005) Watching peptide drugs grow up. Chem. Eng. News 83, 17-24
40. Van Dorpe, S. et al. (2010) Analytical characterization and comparison of the blood-brain barrier permeability of eight opioid peptides. Peptides 31, 1390-1399